EMA Authorised: Apretude (cabotegravir) — ViiV Healthcare B.V.

View source ↗

Summary

The EMA authorised Apretude (cabotegravir) by ViiV Healthcare B.V. for HIV infections, marking EU approval of this long-acting injectable therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• APRETUDE (CABOTEGRAVIR)

Snippet

Status: Authorised. Therapeutic area: HIV Infections. MAH: ViiV Healthcare B.V.. Decision date: 09/12/2024